Agilent (A) Q1 2023: Advanced Materials Surge 20%+ as Oligo Expansion and China Drive Growth Visibility
Agilent’s Q1 performance delivered broad-based double-digit core growth, led by advanced materials and robust China execution, while margin expansion and a $725M oligo capacity build signal management’s conviction in secular demand. Despite macro uncertainty, management raised full-year guidance and continues to see strong order momentum and backlog quality, positioning Agilent for above-market growth through 2023.
Summary
- Advanced Materials and China Outperform: Material science and China both surpassed expectations, driving upside to the quarter.
- Oligo Manufacturing Expansion Signals Confidence: New $725M capacity project and broad pharma partnerships reinforce long-term growth bets.
- Margin Expansion and Prudent Guidance: Operating leverage and cost discipline support raised outlook, but management remains cautious on H2 visibility.
Business Overview
Agilent Technologies provides analytical instruments, software, consumables, and services for laboratories in the life sciences, diagnostics, and applied chemical markets. The company operates through three major segments: Life Sciences and Applied Markets Group (LSAG), which delivers instruments and solutions for chemical analysis; Diagnostics and Genomics Group (DGG), focused on pathology, genomics, and oligonucleotide manufacturing; and Agilent CrossLab Group (ACG), which offers services, consumables, and workflow solutions that attach to Agilent’s installed base. Revenue streams include instrument sales, recurring service contracts, consumables, and custom manufacturing agreements with biopharma clients.
Performance Analysis
Agilent delivered 10% core revenue growth in Q1, with broad-based strength across all major end markets and geographies. Advanced materials, including semiconductors and batteries, led segment performance, with high-20% growth rates, outpacing high single-digit gains in chemicals and energy. The LSAG segment grew 11% core, driven by strong demand for LC, LC-MS, and spectroscopy platforms, while CrossLab posted 13% core growth on record support contract renewals and higher attach rates.
China execution stood out, with 13% growth despite ongoing COVID disruptions, as digital engagement and resilient field teams enabled continued customer support. Operating margin expanded 80 basis points to 27.1%, supported by higher pricing, gross margin gains, and disciplined SG&A. Cash flow from operations rose 16% YoY, supporting a 7% dividend increase and a new $2B share repurchase authorization.
- Material Science and Environmental Tailwinds: Semiconductor, battery, and PFAS testing demand drove outsized growth and backlog.
- Diagnostics Mixed, Genomics Soft: Pathology delivered double-digit growth, but genomics saw double-digit declines amid customer destocking and industry headwinds.
- Order Momentum and Backlog Quality: Orders outpaced revenues, with minimal cancellations and healthy deal pipelines, providing strong near-term visibility.
Management raised full-year core revenue and EPS guidance, citing robust Q1 execution and improved FX outlook, but signaled prudence given macro and backlog normalization dynamics.
Executive Commentary
"Q1 was another outstanding example of the work we've done to build a resilient company with multiple growth drivers. Those growth drivers created through targeted investments that aim to expand and enhance our business' high growth areas are the heart of our build and buy growth strategy."
Mike McMullen, President and CEO
"We are extremely pleased with our Q1 performance. It was a very solid start to the year. Q1 revenue was $1.76 billion, exceeding our expectations. Revenues were up 10% core and 5% on a reported basis. Currency was a five-point headwind, which was an improvement from the beginning of the quarter..."
Bob McMahon, Senior Vice President and CFO
Strategic Positioning
1. Advanced Materials and Semiconductor Demand
Agilent’s portfolio strength in atomic spectroscopy and material science is driving above-market growth in semiconductors and batteries, with high-20% expansion in advanced materials. Government funding for semiconductor manufacturing and persistent demand for lithium battery testing position Agilent to benefit from secular infrastructure and electrification trends.
2. Oligonucleotide Manufacturing Expansion
The $725M NASD capacity expansion will double oligo manufacturing, targeting siRNA, antisense, and CRISPR therapeutics. With 30+ pharma partners and dozens of programs, Agilent is cementing its leadership in a market expected to grow from $1B to $2.4B by 2027. The build-out, called Project Endeavor, reflects management’s conviction in durable demand and market share gains.
3. CrossLab Services and Workflow Attach
CrossLab continues to deliver double-digit growth, leveraging a growing installed base and rising attach rates for services and consumables. Each percentage point increase in attach rate equates to $30M in annual revenue, and management sees further runway as workflow integration deepens, especially in biopharma and environmental applications.
4. China and Geographic Diversification
China delivered 13% growth, outperforming industry peers due to digital engagement and resilient local teams. While Agilent is not yet factoring potential Chinese stimulus into guidance, the company’s legacy presence and diversified end-market exposure position it to capture upside if government investment accelerates.
5. Prudent Guidance Amid Macro Uncertainty
Despite strong Q1 results, management maintained a prudent stance for H2, citing normalization of deal cycles and ongoing macroeconomic volatility. The raised midpoint of full-year guidance reflects confidence in near-term execution, but leadership is taking a quarter-by-quarter approach on volume and pricing assumptions.
Key Considerations
Agilent’s Q1 demonstrated a well-diversified, resilient business model with multiple secular growth vectors, but also revealed areas of caution and transition. Investors should weigh the following:
- Secular Growth in Advanced Materials: Semiconductor and battery demand, supported by government funding, provide a multi-year tailwind for instrumentation and consumables.
- Oligo Market Leadership and Expansion: The $725M NASD investment and a broad pharma pipeline underpin Agilent’s ambition to dominate the oligo manufacturing market.
- Genomics Softness as a Watchpoint: Industry-wide genomics headwinds and customer destocking led to a double-digit decline, though management sees this as transitory.
- Pricing Power and Margin Expansion: Sustained 3% price contribution and disciplined cost management drove margin gains, but volume growth normalization is anticipated in H2.
- Geographic Strength and Stimulus Optionality: China’s outperformance and potential benefit from government stimulus remain underappreciated levers for upside.
Risks
Agilent faces macroeconomic and currency volatility, with management highlighting uncertainty in H2 order patterns and deal cycle normalization. Genomics market weakness and customer destocking pose near-term headwinds. The company’s exposure to capital spending cycles in pharma, chemicals, and academia could impact growth if budgets tighten. While backlog quality remains high, any material slowdown in order rates or increased cancellations would challenge the raised outlook.
Forward Outlook
For Q2, Agilent guided to:
- Revenue of $1.655B to $1.680B, core growth of 6% to 7.5%
- Non-GAAP EPS of $1.24 to $1.27, up 10% to 12% YoY
For full-year 2023, management raised guidance:
- Core revenue growth of 5.5% to 6.5% (midpoint 6%)
- Non-GAAP EPS of $5.65 to $5.70
Management cited continued strong order momentum, backlog quality, and robust Q1 execution as drivers for the upward revision, but emphasized a prudent approach to H2 given macro and normalization trends.
- Raised capital spending forecast to $500M for oligo expansion
- No China stimulus impact included in guidance; represents potential upside
Takeaways
Agilent’s Q1 results reinforce its status as a diversified, execution-driven growth compounder, with advanced materials and oligo manufacturing as standout engines.
- Secular Growth Engines: Advanced materials, semiconductors, and oligo manufacturing are driving above-market growth and visibility into 2024 and beyond.
- Margin and Cash Discipline: Margin expansion and strong cash flow support ongoing capital deployment and shareholder returns.
- H2 Normalization and Macro Uncertainty: Investors should monitor order trends, genomics recovery, and China stimulus deployment for signals on upside or risk to the raised outlook.
Conclusion
Agilent’s diversified growth, margin expansion, and strategic investments in high-growth markets position it to outperform peers, though management’s prudent guidance signals awareness of macro and industry-specific risks. Upside remains tied to continued execution and external demand catalysts.
Industry Read-Through
Agilent’s results highlight secular strength in advanced materials, semiconductors, and battery testing, signaling persistent demand for analytical instrumentation across the materials science ecosystem. The company’s oligo manufacturing expansion and broad pharma partnerships suggest sustained biopharma outsourcing and innovation tailwinds, with implications for peers in contract manufacturing and specialty reagents. Genomics softness and customer destocking are sector-wide, reinforcing caution for suppliers leveraged to NGS and diagnostic testing. Agilent’s China outperformance is a positive read for companies with entrenched local teams and digital engagement, but also underscores the importance of geographic diversification amid global uncertainty.